Delivery Order SPE2DB20D2104-SPE2DB24FV38B
Award Date
7/25/24
Potential Completion Date
7/26/24
Potential Value
$2.4K
Federal Agency
Defense Logistics Agency
Awardee
Amerisourcebergen Drug Corp
Ultimate Awardee
Not listed
NAICS Category
424210 - Drugs and Druggists' Sundries Merchant Wholesalers
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $2,535.06 firm fixed-price delivery order is for the supply of Pulmozyme, a 1 mg/ml ampul medication. The contract has an ultimate completion date of December 12, 2024. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical that serves as a primary vehicle for...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $11,740.65 firm fixed-price delivery order is for the supply of Pulmozyme, a medication used to treat cystic fibrosis. The contract has an ultimate completion date of July 10, 2024. Amerisourcebergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary...
This federal contract award was made by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $77,601.82 delivery order contract is for the supply of Pulmozyme 1 mg/mL ampuls, a medication used to treat cystic fibrosis. The contract is a firm fixed-price, non-set-aside award with a performance period ending on April 29, 2025. AmerisourceBergen Drug Corp holds a substantial $999,999,999.00 Indefinite Delivery...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $7,054.69, is a Firm Fixed Price Delivery Order for the supply of PULMOZYME 1 MG/ML AMPUL 2.5ML, a specialty medication. The contract has an ultimate completion date of March 26, 2025. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical,...
This federal contract award was issued by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a major pharmaceutical distributor. The $34,656.77 firm-fixed-price delivery order is for the supply of Pulmozyme, a medication used to treat cystic fibrosis. This award is associated with a larger Indefinite Delivery Contract (IDC) valued at up to $999,999,999 through December 2025, which enables the DLA to efficiently procure a comprehensive range of medical...
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $14,817.78, is for the delivery of Pulmozyme 1 mg/ml ampul 2.5 ml. This is a firm-fixed-price delivery order contract with an ultimate completion date of August 26, 2024. The contract does not have a set-aside designation, indicating open competition. AmerisourceBergen holds a significant...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $4,988.66 firm fixed-price delivery order is for Pulmozyme 1 mg/mL ampules (2.5 mL) and has a completion date of November 21, 2024. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary vehicle for supplying a broad range of...
This federal contract award, valued at $13,357.18, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corporation, a major pharmaceutical distributor. The award is for a delivery order to supply Pulmozyme 1 mg/ml ampul 2.5 ml, a medication used to treat cystic fibrosis. The contract has a firm fixed price and a performance period ending on April 30, 2025. This award is not designated as a set-aside contract, indicating open competition. AmerisourceBergen Drug...
This federal contract award was made by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the delivery of Pulmozyme 1 mg/mL ampules in 2.5 mL quantities. The contract is a Delivery Order with a Firm Fixed Price type, valued at $8,017.10, and has an ultimate completion date of May 29, 2024. Amerisourcebergen holds a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical valued at up to $999,999,999.00 through...
This federal contract award, valued at $68,193.74, was issued by the Defense Logistics Agency (DLA) Troop Support Medical to the prime contractor Amerisourcebergen Drug Corp for the supply of Pulmozyme 1 mg/ml ampules (2.5 ml). The contract has a firm fixed price and an ultimate completion date of August 14, 2024. Amerisourcebergen, a major pharmaceutical distributor, has been awarded this delivery order under its Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which has a...